MOLECULAR DISSECTION OF ANGIOGENESIS THROUGH GENE DISCOV

描述：(改编自调查人员的摘要)本快速通道阶段 I-阶段II STTR应用的目标是开发一种新的和相关的 研究血管生成(血管生长)的实验系统 这是在合作研究机构开发的。作者 将使用高通量基因发现(全长)的技术平台 已在Origene Technologies，Inc.(OTI)建立。在……里面 这个第一阶段的组件，OTI建议生成表达序列标签 连续开启或关闭的500个基因的(EST) 在他们的实验系统中检测到的血管形成的阶段。 这些EST克隆将为在该阶段进行大规模的cDNA分离奠定基础 二、建议。具体来说，合作研究机构将是 负责分离足够数量的来源RNA，来源是 活体动物模型，在生长信号激活之前和之后，以及 对回收的RNA进行严格的质量控制。基于 已经成功进行的可行性试验结果， OTI将使用源RNA来识别、扩增和测序大约500个 EST代表被抑制或被激活的基因 在模型系统中，内皮细胞开始形成血管。 建议的商业应用：不可用

DESCRIPTION: (Adapted from the investigator's abstract) This Fast-Track Phase I-Phase II STTR application is targeted at exploiting a novel and relevant experimental system for the study of angiogenesis (the growth of blood vessels) that has been developed at the partnering research institution. The authors will use a technology platform for high-throughput gene discovery (full-length cDNA cloning) that has been established at OriGene Technologies, Inc. (OTI). In this Phase I component, OTI proposes to generate expressed sequence tags (EST's) for 500 genes which are either turned on or turned off at successive stages of blood vessel formation as detected in their experimental system. These EST clones will set the stage for large-scale cDNA isolation in the Phase II proposal. Specifically, the partnering research institution will be responsible for isolating sufficient quantities of source RNA derived from the in vivo animal model, both before and after activation by a growth signal, and for performing stringent quality controls on the recovered RNA. Based upon the results of feasibility tests that have already been successfully carried out, OTI will use the source RNA's to identify, amplify, and sequence about 500 EST's which represent genes that are either repressed or activated as endothelial cells begin to form blood vessels in the model system. PROPOSED COMMERCIAL APPLICTION: NOT AVAILABLE